News

Danielle Kipnis, MA, of Columbia University, discussed the practice of yoga for people with functional neurological disorders from her research and recommendations for future studies in the field.

Despite not meeting its primary and secondary end points, CNM-Au8 will continue to be evaluated in an open-label extension in HEALEY ALS and could potentially be offered in an expanded access protocol program.

With diagnosis rates of Alzheimer disease increasing, Tabby Khan, MD, MPH, spoke to the need to focus on cognitive decline in younger patient populations.

Experts such as Brenda Banwell, MD; Sean Pittock, MD; and Michael Levy, MD, PhD, cover topics related to differences in rare neuroimmune disorders, how they're approached and treated.

Findings from a nonrandomized controlled trial in the Netherlands suggest that sleep time of hospitalized patients may be significantly improved with nonpharmacologic interventions such as the postponement of morning vital sign checks and medication administration rounds from the night to the day shift.

The professor of Neurology and Pediatrics at University of Rochester Medical Center discusses the progression of new treatment for Duchenne muscular dystrophy and provides suggestions for moving forward with research in the field. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Designed to treat the underlying cause of FSHD, AOC 1020 will be evaluated on safety, tolerability, pharmacokinetics, and pharmacodynamics in a cohort of 68 adults with the disease.

The professor of neurology and pediatrics at University of Rochester Medical Center gives some recommendations for the improvement in clinical trial design for patients with rare diseases such as Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]

RESCUE-ALS trial, a phase 2 randomized controlled study, showed that ALS disease progression was significantly reduced with CNM-Au8 Treatment.

Justin Klee and Josh Cohen, cofounders and cochief operating officers, Amylyx Pharmaceuticals, answered questions related to the new approval of AMX0035 for ALS and how it changes the treatment landscape going forward.

Neurology News Network for the week ending October 1, 2022. [WATCH TIME: 4 minutes]

Sleep changes experienced by patients on apomorphine infusion were indicated by scores on Insomnia Severity Index and Clinical Global Impression-Improvement Scale.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 23, 2022.

In a randomized clinical trial, the application of electroacupuncture treatment for insomnia in patients with depression significantly improved the quality of sleep in comparison with sham acupuncture or the control group.

The neurologist and assistant professor at the University of Toronto discussed the real, but tepid significance of amyloid-related imaging abnormalities seen from lecanemab in early-stage Alzheimer disease. [WATCH TIME: 3 minutes]

A questionnaire-based study from Saudi Arabia on sleep quality revealed that sleep-related disorders, such as obstructive sleep apnea, are relatively common in patients with Duchenne muscular dystrophy.

Despite not improving clinical end points, treatment with tofersen was associated with reduced in the total concentration of SOD1 protein and neurofilament light chain, a marker of axonal injury.

In additional data from CENTAUR, Amylyx touted the drug's ability to prolong tracheostomy-free and ventilation-free survival.

The clinical program manager at the Jefferson Center for Neurorestoration provided insight on a new myoelectric device designed for restoration of independent arm function in those with neurological diseases. [WATCH TIME: 4 minutes]

After previously failing a phase 3 trial of patients with multiple system atrophy, verdiperstat continued to show an effect in patients with ALS that was similar to those on placebo.

Findings from a cross-sectional survey revealed a significant association between depression and a diagnosis of myotonic dystrophy, and that symptoms impacting quality of life are more common in neuromuscular disorders.

Although data from the EMSES study failed to reveal a reduction in relapse rates or global brain atrophy, half of the important motor-related tracts and nuclei observed displayed higher structural integrity in exercise patients.

The neurologist and assistant professor at the University of Toronto provided insight on positive topline findings from the phase 3 Clarity AD study of lecanemab in early Alzheimer disease. [WATCH TIME: 4 minutes]

A study on ALS progression suggested that tollgate-related prognostic factors have a stronger effect on the time trajectories of passing ALS tollgates in comparison with standard prognostic factors.

Consistent with the overall population, newly diagnosed, treatment-naïve patients with MS showed better relapse rates, all-cause disability worsening—including progression independent of relapse activity—with ofatumumab over teriflunomide.

The pulmonologist at Penn Medicine provided commentary on the pressing issues clinicians continue to face when treating patients with insomnia. [WATCH TIME: 3 minutes]

The professor of neurology and pediatrics at the University of Rochester Medical Center provided insight on the emerging therapies and advancements for treating patients with Duchenne muscular dystrophy.